Comparison of an LH-RH analogue (goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: Final survival results of an international multicentre randomized-trial

European Urology

Volumn 37, Issue 2, 2000, Pages 205-211

  Tyrrell, Chris J ^a   Altwein, J E ^b   Klippel, F ^c   Jurincic Winkler, C ^c   Varenhorst, E ^d   Lunglmayr, G ^e   Boccardo, F ^f   Holdaway, I M ^g   Haefliger, J M ^h   Jordaan, J P ⁱ  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b Barmherzigen Brüder Hospital   (Germany)

^c Academic Hospital   (Germany)

^d Departments of Surgery and Urology   (Sweden)

^e Mistelbach General Hospital   (Austria)

^f UNIVERSITY OF GENOA   (Italy)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h General Hospital   (Switzerland)

ⁱ ADDINGTON HOSPITAL   (South Africa)

Author keywords

Advanced prostate cancer survival; Combined androgen blockade; Flutamide; Goserelin acetate; Luteinizing hormone releasing hormone analogue

Indexed keywords

FLUTAMIDE; GOSERELIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0033984532     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020119     Document Type: Article

References (24)